Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to $35.8 million.

  • Ascendis Pharma A's Share-based Compensation rose 2560.48% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.7 million, marking a year-over-year increase of 3488.32%. This contributed to the annual value of $103.4 million for FY2024, which is 4413.44% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Share-based Compensation of $35.8 million as of Q3 2025, which was up 2560.48% from $34.0 million recorded in Q2 2025.
  • Ascendis Pharma A's Share-based Compensation's 5-year high stood at $35.8 million during Q3 2025, with a 5-year trough of $13.6 million in Q3 2022.
  • For the 5-year period, Ascendis Pharma A's Share-based Compensation averaged around $22.1 million, with its median value being $19.7 million (2021).
  • As far as peak fluctuations go, Ascendis Pharma A's Share-based Compensation soared by 6866.91% in 2021, and later crashed by 3444.29% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Share-based Compensation stood at $16.2 million in 2021, then fell by 12.54% to $14.2 million in 2022, then increased by 20.93% to $17.1 million in 2023, then skyrocketed by 63.7% to $28.0 million in 2024, then increased by 27.82% to $35.8 million in 2025.
  • Its Share-based Compensation stands at $35.8 million for Q3 2025, versus $34.0 million for Q2 2025 and $26.9 million for Q1 2025.